Driehaus Capital Management 13F: Cuts SEPN Stake by $14M

Driehaus Capital Management has reduced its stake in Septerna, Inc. (NasdaqGM: SEPN). According to the latest Form 13F filing with the SEC, Driehaus trimmed its holdings by 413,898 shares, or 8.6%, leaving it with 4,395,572 shares valued at approximately $158 million as of the reporting period.

What Changed in Driehaus Capital Management's Septerna, Inc. Position

Driehaus Capital Management's decision to reduce its position in Septerna, Inc. saw its holdings drop from 4,809,470 shares to 4,395,572 shares. This change represents a decrease of 8.6% and reflects a shift in the fund's investment strategy regarding the biotechnology firm.

Other Institutional Activity in Septerna, Inc.

Among Septerna, Inc.'s other institutional investors, RA Capital Management maintained its stake at 6,995,858 shares, valued at $168 million. TRV GP V, LLC also held steady with 6,215,591 shares worth $149 million. Meanwhile, TRV GP VI, LLC kept its 4,211,659 shares, valued at $101 million. Samsara Biocapital, LLC held onto its 3,149,128 shares, valued at $75 million. In contrast, Goldman Sachs Group Inc. increased its holdings by 191,298 shares, bringing its total to 2,906,427 shares valued at $69.8 million.

Septerna, Inc. Stock Down 13.4%

Shares of Septerna, Inc. are currently trading at $35.95. The company has a market capitalization of around $1.62 billion. Septerna's forward P/E ratio is not meaningful as the company is not profitable, reporting an EPS of -$0.80. The stock has a 52-week range between $9.85 and $36.26, with a 50-day moving average of $26.87 and a 200-day moving average of $24.30. The company maintains a strong liquidity position with a current ratio of 4.71 and a quick ratio of 4.63, while its debt-to-equity ratio stands at 6.10.

Recent Earnings

Septerna, Inc. reported revenue of $72.3 million, reflecting a significant growth rate of 120.11%. Despite this, the company has a negative net margin of 49.88% and a return on equity of -9.26%. Investors can look forward to the next earnings report, scheduled for August 10, 2026.

Insider Buying and Selling at Septerna, Inc.

Chief People Officer Samira Shaikhly was active in recent insider transactions. On June 1, 2026, she sold 5,935 shares at an average price of $28.92 under a pre-planned 10b5-1 trading plan. On May 26, she sold another 11,798 shares at $30.06, also under a planned transaction.

Analysts Set New Price Targets

On June 8, 2026, Raymond James maintained a 'buy' rating for Septerna, Inc., setting a price target of $53. Other firms like JP Morgan and Wells Fargo have also maintained 'buy' ratings, with targets of $38 and $48, respectively. The consensus among analysts is a 'strong buy,' with a mean target price of $45.78 based on nine analyst opinions.

About Septerna, Inc.

Septerna, Inc. is a biotech company based in South San Francisco, California. It focuses on developing oral small molecule therapies targeting G protein-coupled receptors (GPCRs) for various diseases, including endocrinology, immunology, and metabolic conditions. The company is led by CEO Dr. Jeffrey T. Finer and employs about 130 people. Septerna collaborates globally with Novo Nordisk to advance therapies for metabolic diseases.

Bottom Line

Driehaus Capital Management's reduction in Septerna, Inc. reflects a strategic adjustment, yet the company remains a significant player in biotech. Investors keep a close watch on Septerna's development in GPCR-targeted treatments and its collaboration with Novo Nordisk. As always, remember that 13F filings are backward-looking and may not reflect current positions.